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Abstract
Background: The Joint Asia Diabetes Evaluation (JADE) Program is a web-based program incorporating a 
comprehensive risk engine, care protocols, and clinical decision support to improve ambulatory diabetes care.
Methods: The JADE Program uses information technology to facilitate healthcare professionals to create a diabetes 
registry and to deliver an evidence-based care and education protocol tailored to patients' risk profiles. With written 
informed consent from participating patients and care providers, all data are anonymized and stored in a databank to 
establish an Asian Diabetes Database for research and publication purpose.
Results: The JADE electronic portal (e-portal: http://www.jade-adf.org) is implemented as a Java application using the 
Apache web server, the mySQL database and the Cocoon framework. The JADE e-portal comprises a risk engine which 
predicts 5-year probability of major clinical events based on parameters collected during an annual comprehensive 
assessment. Based on this risk stratification, the JADE e-portal recommends a care protocol tailored to these risk levels 
with decision support triggered by various risk factors. Apart from establishing a registry for quality assurance and data 
tracking, the JADE e-portal also displays trends of risk factor control at each visit to promote doctor-patient dialogues 
and to empower both parties to make informed decisions.
Conclusions: The JADE Program is a prototype using information technology to facilitate implementation of a 
comprehensive care model, as recommended by the International Diabetes Federation. It also enables health care 
teams to record, manage, track and analyze the clinical course and outcomes of people with diabetes.
Background
In this pandemic of diabetes, Asia has the highest number
of affected individuals with a disproportionate increase in
the young to middle aged group [1,2]. Although diabetes
reduces life expectancy by an average of 10-12 years [3],
diabetes and associated complications are highly prevent-
able and treatable [4-7]. Using a comprehensive diabetes
registry established since 1995, our group has developed
a series of risk equations [8-14] to predict all-cause death
and cardiovascular-renal outcomes in Chinese type 2 dia-
betic patients. Our group and others have also reported
50-70% risk reduction in these clinical outcomes amongst
patients receiving protocol-driven care delivered by a
multidisciplinary team compared to usual care [15-20].
In 2006, we developed a web-based Joint Asia Diabetes
Evaluation (JADE) Program to combine the concepts of
risk stratification and protocol-driven care to translate
evidence to practice using information technology. In the
past years, various computerized systems have been
developed to facilitate management of diabetes or cardio-
vascular disease [21-26]. Most of the systems were data
registries though some of them incorporated clinical
practice guidelines and/or performance feedback. How-
ever, a comprehensive and easily accessible electronic sys-
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tem which integrates primary and secondary care with
decision support, risk stratification and interactive feed-
back, as recommended by the International Diabetes Fed-
eration [27], is still lacking. In this program, we used an
electronic portal (e-portal) to facilitate health care team
to implement evidence-based care protocol and empower
patients to improve self management. The administration
of the Program is supported by a multidisciplinary team
including a part-time endocrinologist, programmer, proj-
ect coordinator. The e-portal is designed specifically to
cater the needs of Asian countries in terms of language
and risk equations which stratify patients into 4 care lev-
els to guide clinical management, although these features
can be easily adapted for other populations. The e-portal
also generates concise graphic reports for both patients
and physicians highlighting trends of "ABC" targets (i.e.
glycated hemoglobin [HbA1c], blood pressure [BP] and
low-density lipoprotein cholesterol [LDL-C]) to facilitate
individualizing treatment. We have reported the internal
validation of the JADE Risk Engine [28] using a registry
consisting of 7534 type 2 diabetic patients. Herein, we
report the technical details of the design and implemen-
tation of this web-based program.
Results
The JADE portal is available to registered users since
November 2007. In this early phase of implementation,
we have limited the number of users by invitation to gain
feedback, assess need of technical support and refine the
Program. Eleven Key Opinion leaders from 8 countries or
areas in Asia (China, Hong Kong, Taiwan, Singapore,
Malaysia, Thailand, Philippines and Korea) were invited
to form a Steering Committee. These steering committee
members recommended appropriate clinicians in their
countries to the JADE Portal Support Office (PSO). After
registration, these clinicians were granted a log-in
account with password.
JADE e-portal http://www.jade-adf.org
Figure 1 summarizes the key features of the JADE e-por-
tal as a Java application using the Apache web server, the
mySQL database and the Cocoon framework. The user
input is validated both on the server-side and client-side,
which is aligned with industry best coding practices. The
validation technique prevents attackers from inserting
potentially harmful syntax into the web application,
which could then potentially be sent to the application
server or backend database residing inside the network
infrastructure. The system was developed in a secure
manner and externally assessed by Cybertrust Inc.
Through SQL injection, cross-site scripting and parame-
ter manipulation, it was unable to gain session hijacking
and authentication bypass.
The JADE e-portal includes a validated risk engine for
risk stratification based on data collected during the
annual comprehensive assessment. Based on the patient's
risk level, a care protocol is recommended with clinical
decision and self management support. The e-portal also
provides user-friendly templates to guide users to collect
relevant clinical data during the annual comprehensive
assessment visit including eye and foot examination,
blood and urine tests, medications, major medical events
and quality of life. The British National Formulary was
used as a framework to classify medications for data cap-
ture and future analysis.
At each review visit, key parameters as recommended
by international guidelines are captured to document
clinical progress. These include BP, body weight, risk fac-
tor control (e.g. HbA1c, lipid, renal function, albuminu-
ria), self care, hypoglycemia and admissions since last
visit (Figure 2, showing the comprehensive assessment
webpage). These data can be collected on line at point-of-
care, or offline using paper format followed by date entry
to the e-portal at a later stage, depending on the clinic set
up and operation. All patients are given unique identifica-
tion codes and each visit is dated to avoid double entry.
All data are locked 12 weeks after the input to prevent
'back-date' data manipulation. However, through request
to the PSO with clear explanation, unlocking of the rele-
vant data for editing or deletion is possible. The timing of
12 weeks for data locking was selected since this was the
average turnover time for return of laboratory results and
data input in various Asian countries.
Based on results estimated by the JADE Risk Engine,
the e-portal displays the 5-year probability of major clini-
cal events which can be adjusted by changing values of
modifiable risk factors to promote discussions between
patients and care providers (Figure 3). Data collected at
each review visit are displayed to show the trends of con-
trol of modifiable risk factors including BP, HbA1c, LDL-
C and body weight. General recommendations can be
triggered by predefined levels of risk factors to prompt
care providers and patients to take appropriate actions.
Printable reports showing risk predictions, trends of risk
factor control and practice tips can be generated for care
providers (in English) and patients (in 5 different Asian
languages i.e. English, Thai, Korean, Malay and Chinese
[both traditional and simplified Chinese]) for record pur-
pose (Figure 4). Furthermore, the portal provides
matrixes to help doctors monitor patients' levels of
adherence to care processes (e.g. annual assessment,
review visits, education sessions, laboratory tests) and
self management as well as their status of attainment of
treatment targets. These targets can be modified depend-
ing on the evolution of international healthcare stan-
dards.Ko et al. BMC Medical Informatics and Decision Making 2010, 10:26
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Up to 1st  January 2010, 10,164 patients from Hong
Kong, Taiwan, Singapore, Thailand, Philippines, Korea,
India and Brunei have joined the JADE Program. The
Program is scheduled to be launched in Mainland China
in mid 2010.
Discussion
Although optimal management of risk factors and treat-
ment to targets can substantially reduce risk of diabetic
complications [4-6,29-32], there are multiple barriers at
the system, care providers and patients' levels to translate
these evidence to clinical practice. These include the
complex nature of care protocols, need to interpret large
amount of interrelated clinical information, demands on
patients' self discipline as well as lack of time and
resources for counseling and reinforcement of compli-
ance. In most national or international surveys, standards
of diabetes care remain suboptimal often due to low
adherence to treatment guidelines and clinical inertia on
the part of care providers and low levels of compliance
with drugs and self care by patients [33-37].
Motivated by improved risk factor control and clinical
outcomes in patients randomized to clinical trials [18,38],
our group and others have demonstrated that delivery of
protocol-driven care using a multidisciplinary team with
particular focus on risk stratification, periodic assess-
ments, treatment to target and reinforcement of treat-
ment compliance including use of telephone counseling
can reduce risk of all-cause death and cardio-renal out-
comes by 50-70% [6,17-19,33,38-41].
Using these prototypes of care models as templates and
through private-public partnerships, we used state of the
art information technology to develop the JADE Program
as a regional quality improvement program. We also used
this virtual platform to promote collective learning and
sharing of best practices based on evidence pertinent to
Asian populations. The latter include the lower cutoff
values for body mass index and waist circumference to
define overweight/obesity as well as the high predictive
values of renal function, albuminuria and low blood
hemoglobin for cardiovascular disease. The JADE Pro-
gram also displays trend lines with prompts and recom-
mendations to reinforce key messages and empower
patients and care providers to make informed decisions.
Most importantly, health care teams can use the JADE e-
portal to create its own diabetes registry to detect
defaults, monitor clinical progress and track key perfor-
mance indexes (e.g. attainment of treatment targets) of
their patients for continuous quality improvement.
Supported by the JADE Project team and the Steering
Committee, the JADE Program also provides a virtual
platform to promote collaborative research to address
epidemiological and therapeutic questions pertinent to
Asian populations. The establishment of the Asia Diabe-
tes Database using the JADE e-portal aims to refine the
accuracy and applicability of various risk equations to dif-
ferent Asian populations. By recording essential clinical
data on an ongoing basis as recommended by interna-
tional guidelines, the impact of adherence to medications
and care processes by patients (e.g. self blood glucose
Figure 1 Logistics and components of the web-based electronic portal of the JADE Program.
Role-based access: 
 Local – Clinic / Hospital 
 Sub-region – City 
 National – multi-country 
Phased Web Portal 
(JADE Program portal) 
Data input Patient Registry 
(governed by access control rules)
Data Mining 
Risk 
Engine
Structured care protocol rules  Reporting Risk Engine 
 Protocol guidance 
 Risk assessments 
 Ad hoc queries 
Built-in portal features included 
prompts, triggers & recommendations 
and estimated future risk of diabetic 
Other functions: 
Printable doctors’ summary & 
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monitoring) and care providers (e.g. annual assessment
and laboratory investigations); use of non-pharmacologi-
cal (e.g. diabetes education, lifestyle modification) and
pharmacological interventions as well as their interac-
tions with various phenotypes and secular changes on
clinical outcomes can be monitored and analyzed [42-44].
Limitations
The JADE Program is designed for diabetes and associ-
ated conditions and complications. It is disease specific
that limits its application in non-diabetic subjects. How-
ever, diabetes is common and complex, for which a spe-
cific and comprehensive management tool is indicated. In
addition to using graphic reports to motivate self man-
agement, there are rooms for further improvement such
as education on appropriate drug use and medication
adherence. Continuous review of the e-portal in terms of
user-acceptability and recommendations based on evolv-
ing evidence is the major task of the JADE Project team.
Of note, in order to fully utilize the features of the JADE
e-portal, there is a need to modify the clinic practice to
deploy trained non-medical personnel, e.g. nurses and
physician assistants (e.g. high school or university gradu-
ates) to perform clinical assessments, enter data and
remind doctors and patients to adhere to recommended
treatments or procedures. Currently the JADE Project
team is organizing a 1-2 day training program to share
experience with health care teams on how to reorganize
the clinic setting in order to use the e-portal more effec-
tively using a multidisciplinary care model. Given the
complex nature of diabetes and pluralistic needs of those
affected, in spite of the state of the art information tech-
nology, a competent and caring clinical team remains the
essence of quality diabetes care [21,45,46].
Conclusions
We combined the concept of risk stratification and multi-
disciplinary care to use information technology to facili-
tate implementation of evidence-based diabetes care
protocols. Using a multidisciplinary approach, doctors
can use the JADE e-portal to reorganize the process of
care delivery and establish a diabetes registry to manage,
track and analyze the large amount of clinical informa-
tion to improve decision making. On a research front, the
Figure 2 The JADE electronic portal provides templates to guide users to collect relevant data during the annual comprehensive assess-
ment.Ko et al. BMC Medical Informatics and Decision Making 2010, 10:26
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JADE Program provides a virtual platform to collect epi-
demiological data and implement disease management
programs to improve our understanding of the natural
history of diabetes and evaluate effectiveness of various
intervention in a pragmatic, naturalistic and scientific
setting.
Methods
Objective and Design of the JADE Program
The objective of the JADE Program is to use information
technology to facilitate health care team to deliver high
quality diabetes care so as to reduce complication rates
and improve self care. Figure 1 summarizes the logistics
and components of the JADE e-portal including role-
based access rules, a risk engine, a diabetes registry and
care protocols with reporting function. All enrolled
patients gave written informed consent to submit their
anonymized data for joint analysis. These data include
clinical and demographic information and laboratory
investigations during regular comprehensive assessments
and regular follow-up visits. All participating doctors
gave written informed consent and indicated their under-
standing of the rationale, purpose and implementation
p r o c e s s  o f  t h e  J A D E  P r o g r a m .  T h i s  J A D E  e - p o r t a l  i s
available on the internet and targeted at both specialists
or primary care doctors who look after diabetic patients
in solo practice, public health institutions, health mainte-
nance organizations (HMO) or non-government organi-
zations (NGO).
Risk Stratification and Care Management Level
The risk stratification program was based on 4 clinical
parameters: 1) stratification parameters such as smoking
status; 2) estimated glomerular filtration rates (eGFR); 3)
risk scores derived from the Hong Kong Diabetes Regis-
try Risk Equations; and 4) the existence of any known car-
diovascular-renal complications (table 1) [8-14,27,28,47-
50]. The internal validation of this risk stratification pro-
gram has been reported [28]. In brief, based on these 4
sets of parameters collected during an annual compre-
hensive assessment, patients can be categorized into one
of the 4 care levels: 1) Very High Risk (VHR) group with
clinically evident cardiovascular-renal complications; 2)
H i g h  R i s k  ( H R )  g r o u p  w i t h  3  o r  m o r e  s t r a t i f i c a t i o n
parameters, or values above the high specificity cutoff for
any one of the risk scores, or eGFR <60 ml/min/1.73 m2;
Figure 3 The JADE Risk Engine estimates the 5-year probability of major clinical events.Ko et al. BMC Medical Informatics and Decision Making 2010, 10:26
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3) Medium Risk (MR) group with 2 stratification parame-
ters, and/or values above the high sensitivity cutoff but
lower than the high specificity cutoff for any of the risk
scores, and/or eGFR between 60 and 90 ml/min/1.73 m2;
and 4) Low Risk (LR) group with one or fewer stratifica-
tion parameter, and values below the high sensitivity cut-
off for all risk scores, and eGFR ≥ 90 ml/min/1.73 m2.
Based on these risk levels, a care protocol with pre-
defined schedules and decision support is recommended
[28]. Depending on the risk level, the e-portal will recom-
mend intervals between review visits, laboratory tests
and complication assessments. The risk level is estimated
based on a comprehensive set of data collected at presen-
tation and then 12-24 monthly thereafter for quality
assurance and re-evaluation of risk level. Hence, the risk
level, and corresponding management plan, may change
according to the clinical status to promote cost-effective
use of finite resources. Using charts and trend lines, phy-
sicians are encouraged to individualize therapies based
on patients' profile and trend of 'ABC' targets to promote
self care and reduce clinical inertia. The value of early
intervention is now clearly confirmed by the legacy effect
of attaining glycemic control early to reduce risk of future
complications [7]. Although similar legacy effect has not
been confirmed for dyslipidemia and blood pressure [51],
optimal treatment of these conditions has been shown to
reduce cardio-renal complications in both primary and
secondary prevention [6].
Self management support
The JADE e-portal generates patients' report in simple
layman terms and displays the trends of HbA1c, BP and
LDL-C in diagrammatic forms. There are also prompts
and practice tips on lifestyle and use of medication to
achieve recommended treatment targets (i.e. HbA1c <7%,
BP <130/80 mmHg, LDL-C <2.6 mmol/L) [27,28,49,50].
At each visit, the e-portal re-estimates the 5-year proba-
bility of cardio-renal complications using the most
updated clinical information of the patient, notably, risk
factors which are modifiable. To this end, there is evi-
dence suggesting that awareness of complications, health
literacy [52] self efficacy and expectation of improved
clinical outcomes [53] are associated with improved met-
abolic control and self care in diabetic patients. While the
Figure 4 The JADE e-portal displays the risk level of the patients, supplemented by decision and self management support triggered by 
various risk factors which can be printed in 5 Asian languages.Ko et al. BMC Medical Informatics and Decision Making 2010, 10:26
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JADE Program uses care level and risk prediction to
empower patients, additional input by the health team
will be needed, e.g. referral to dietitians or nurse educa-
tors or drug titration or change of medications.
Governance, technical support and data security
The JADE Program is governed by the Board of Directors
of the Asia Diabetes Foundation (ADF) which is a non-
profit making organization incorporated under the Chi-
nese University of Hong Kong (CUHK) Foundation. It is a
charitable body approved by the Tax and Revenue
Department of the Hong Kong Government with a mis-
sion to promote awareness and facilitate academic
research to improve chronic disease management includ-
ing diabetes. Hitherto, access to the JADE e-portal is by
invitation and free of charge. The ownership and liability
of the Program as well as all collected data and subse-
quent deliverables including publications belong to the
ADF.
On an academic front, the JADE Steering Committee
consists of leading diabetologists from Asia who provide
overall direction and monitor progress of the Program.
Members of the JADE Steering Committee also serve as
local champions to promote the adoption of the JADE
Program in their country. The JADE Project team con-
sists of a medical director working closely with the Infor-
mation Technology Team, PSO and a supporting team in
each participating country.
To limit the impact of potential exposure or leakage of
patient information, the JADE Program does not store
any identifying patient information electronically. No
name or national identity number is captured and a case-
specific code (ADF code) is generated for each enrolled
patient. Only the physician has the information to iden-
tify the patient given a specific ADF code. These case sen-
sitive codes are known to the patients and all report
forms generated electronically or in paper form, are kept
by the physicians or in the case records as appropriate.
Registered users, who are usually the doctor in charge of
the clinic, can grant access rights to other clinic staff.
These assistant personnel need to provide written con-
sent and abide to the terms of reference of ADF before
they can use the e-portal and have access to these anony-
mized data which can be decoded using the patient log
kept at the clinic. At the time of writing, patients are
given printed reports which summarize their risk levels,
5-year risk of major events and key clinical parameters.
They do not have access to their raw data electronically,
although this feature can be incorporated at a later stage,
depending on the uptake of the Program.
All data are given a 'reasonable' range for acceptance
and will generate a prompt if data are above or below the
range. The validity of all clinical information is checked
periodically by a monitoring team designated by the
JADE Project team to ensure the quality and integrity of
these data for analysis purpose. While the monitor can-
Table 1: Parameters used in the Joint Asia Diabetes Evaluation (JADE) electronic portal to derive the Care Management 
Level in Type 2 Diabetic Patients.
Derivation parameters Details
1. Clinically evident 
cardiovascular-renal 
complications
History of stroke, coronary heart disease, non-fatal heart failure, peripheral vascular disease, end stage 
renal disease (dialysis or eGFR <15 ml/min/1.73 m2)
2. Risk stratification 
parameters
Current or ex smoker
BMI ≥ 27.5 kg/m2 or waist circumference ≥ 80 cm in women or ≥ 90 cm in men
Blood pressure >130/80 mmHg or treatment with anti-hypertensive drugs
LDL-C >2.5 mmol/l
TG ≥ 2.3 mmol/l &/or HDL-C <1 mmol/l
Treatment with lipid regulating drugs if LDL-C ≤ 2.5 mmol/l and TG <2.3 mmol/l and HDL-C ≥ 1.0 mmol/l
Spot morning urine for ACR >3.5 mg/mmol in women or >2.5 mg/mmol in men
Foot at risk defined by 2 of 3 of the following: sensory neuropathy, skin changes (e.g. fungal infection, dry 
skin) or deformities (e.g. claw feet or hallux deformities)
Retinopathy
HbA1c ≥ 8%
3. Hong Kong Diabetes 
Registry Risk Scores
High sensitivity and specificity cutoff points for various clinical endpoints (stroke, coronary heart disease, 
end stage renal disease and heart failure)
4. Renal function eGFR by the MDRD equation
eGFR, Estimated glomerular filtration rate; BMI, body mass index; LDL-C and HDL-C, low- and high-density lipoprotein cholesterol; TG, 
triglyceride; ACR, albumin creatinine ratio; HbA1c, glycated hemoglobin; MDRD, Modification of Diet for Renal Disease (ref. [40])Ko et al. BMC Medical Informatics and Decision Making 2010, 10:26
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not change any data, he/she can flag reminders to the
local supporting team when suspicious data is encoun-
tered such as large discrepancy in body mass index and
waist circumference. For errors noted after the data has
been locked, the corresponding user can request data
unlocking for amendment. All editing activities are
tracked and recorded by the PSO.
Apart from using anonymized data, the JADE e-portal
also adopts the strictest security industry practices.
These include end-to-end data encryption of the grade
used by most online banking sites, user authentication,
information access control mechanisms, and dedicated
server hosting with physical access control to the facili-
ties. In July 2007, Cybertrust Inc., an established and spe-
cialized security company, was commissioned to perform
an independent security assessment of the application of
the JADE e-portal. Cybertrust conducted both black box
and white box security testing of the application, and ver-
ified that the JADE e-portal performed reliably and
securely when tested with automated and manual attack
techniques.
Institutional board review and ethics approval
The establishment of the Asia Diabetes Database using
the JADE e-portal was approved by the Clinical Research
Ethics Committee of the Chinese University of Hong
Kong. Implementation of the JADE Program was also
approved by the relevant institutional review board in
individual countries through submission by the Steering
Committee members. All patients were given detailed
information sheet on the background, purpose and pro-
cesses of the JADE Program. Written consent was
obtained from each participant to undergo comprehen-
sive assessment at enrolment and at regular intervals
thereafter. Participating doctors and care providers also
gave written informed consent indicating their under-
standing and willingness to promulgate the vision and
mission of the JADE Program to improve ambulatory dia-
betes care.
Portal Support Office (PSO)
The Information Technology team based at the JADE
PSO supports all program-related technical and logistic
matters encountered by the users. The PSO organizes
meetings with the JADE supporting teams in different
countries on a regular basis to collect feedback and
explain changes to the e-portal, as appropriate. All users
are provided a manual of frequently asked question
(FAQ) about the JADE e-portal. The PSO also provides
information on evidence-based management plan of
updated versions, scheduled maintenance, bug reports
and technical tips. The service commitment in support-
ing on-line enquiry of the PSO include response time in 2
working days and resolution time in 2 to 7 days depend-
ing on complexity of the enquiries.
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